Search company, investor...


Founded Year



Series B | Alive

Total Raised


Last Raised

$20M | 6 mos ago

About Aravax

Aravax is a biotechnology company that develops peptide-based immunotherapy. The company uses proprietary technology to reset the immune system to tolerate allergens without evoking allergic reactions during treatment. Its product includes PVX108 which is a treatment for peanut allergy. Aravax was founded in 2015 and is based in Melbourne, Australia.

Headquarters Location

31 Queen St Level 9

Melbourne, Victoria, 3000,


+61 (0) 3 9657 0700

Missing: Aravax's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Aravax's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Aravax

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aravax is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Aravax Patents

Aravax has filed 4 patents.

The 3 most popular patent topics include:

  • Allergology
  • Clusters of differentiation
  • Cytokines
patents chart

Application Date

Grant Date


Related Topics




Immune system, Immunology, Clusters of differentiation, Allergology, Food allergies


Application Date


Grant Date



Related Topics

Immune system, Immunology, Clusters of differentiation, Allergology, Food allergies



Latest Aravax News

Aravax doses first patient in Phase 2 peanut allergy clinical trials

Jun 1, 2023

닫기 MELBOURNE, Australia, June 1, 2023 /PRNewswire/ -- The first patient has been dosed in a Phase 2 study (AVX-201) being run by biotechnology company Aravax, which is developing the novel therapy PVX108 for the safe and convenient treatment of peanut allergy. The study is being conducted under a U.S. FDA Investigational New Drug Application. Allergy clinical trial centres across Victoria, South Australia, New South Wales, and Western Australia have invited children and adolescents aged four to 17 years with peanut allergy to take part in the Phase 2 study. Researchers aim to evaluate the efficacy of the novel therapy PVX108. In Phase 1 trials, researchers observed that PVX108 produced relevant changes in the immune response to peanut protein, which continued to develop once dosing had completed. "We're thrilled to have dosed our first patient in Phase 2. In this Phase 2 trial we will evaluate how the immunological changes observed in Phase 1 trials translate to clinical reductions in allergic reactivity and the development of tolerance to peanuts following 12 monthly doses of PVX108," says Dr Pascal Hickey, CEO, Aravax. Unlike most treatments available or under development for peanut allergy, Aravax's PVX108 does not contain peanut proteins which put patients at risk of serious side effects. Aravax is applying its platform technology to develop specific immunotherapies for food allergies which are designed to precisely retrain the immune system to tolerate peanut allergens. These therapies are anticipated to be highly differentiated based on greatly improved safety profile, and the potential for sustained clinical benefits possibly leading to reversal of allergic disease. Clinical trial AVX-201 is led in Australia by regional principal investigator Associate Professor Kirsten Perrett, Population Allergy Group Leader at the Murdoch Children's Research Institute. Associate Professor Perrett is also a Paediatric Allergist and Vaccinologist and Director of the National Allergy Centre of Excellence (NACE). Aravax will be attending BIO 2023 in Boston next week, and, Chief Scientific Officer Sara Prickett will be speaking at the European Academy of Allergy & Clinical Immunology Congress 2023 (Hamburg, 9-11 June), in a presentation titled: 'A Peptide Immunotherapy for Peanut Allergy Safely Induces Durable Immune Changes in Peanut-Allergic Adults'. "I'm excited to be speaking at EAACI to some of the world's top immunology experts about the great progress being made at Aravax to tackle peanut allergies, an issue that affects millions of people globally. I've seen the impact that peanut allergies not only have on patients, but also families," Prickett says. Aravax's Phase 2 trials of PVX108 follow on from $20m investment as part of its series B funding round, led by Australian life science investors, Brandon Capital and Tenmile. More information and details on how to apply to participate in the clinical trial can be found on the on the NACE  and Aravax  websites. CONTACT: Ciara Byrne, 출처 : PR Newswire 보도자료

Aravax Frequently Asked Questions (FAQ)

  • When was Aravax founded?

    Aravax was founded in 2015.

  • Where is Aravax's headquarters?

    Aravax's headquarters is located at 31 Queen St, Melbourne.

  • What is Aravax's latest funding round?

    Aravax's latest funding round is Series B.

  • How much did Aravax raise?

    Aravax raised a total of $24.9M.

  • Who are the investors of Aravax?

    Investors of Aravax include Brandon Capital, Tenmile, Monash University and Alfred Health.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.